US Stock Market Move | Withdrawal of experimental drug riluzole application in the EU market leads to a 21% drop in Biohaven (BHVN.US) stock.
On Friday, Biohaven (BHVN.US) plunged during trading hours, with the decline widening to 21% at one point, and is now trading at $20.62.
On Friday, Biohaven (BHVN.US) plunged during trading, with the decline reaching 21% at one point, and is now trading at $20.62. On the news front, the company has withdrawn its application for the experimental drug Troriluzole in the EU market. This drug has been studied as a potential treatment for Machado-Joseph disease, OCD, and glioblastoma.
RECOMMEND
Pan Gongsheng: Will implement a moderately loose monetary policy to promote high-quality development of the Chinese economy.
25/04/2025
Canadian Prime Minister Trudeau: No rush to reach agreement with Trump, US side eventually needs to face reality.
25/04/2025
Alphabet (GOOG.US, GOOGL.US) first quarter revenue and profits exceed expectations, driven by AI and cloud computing performance growth.
25/04/2025
